SYMPHONY-PE Analysis Shows Early Thrombectomy Linked to Better Outcomes

June 19, 2026—Imperative Care announced findings from a post hoc analysis of the SYMPHONY-PE trial that suggest that mechanical thrombectomy performed within 12 hours of diagnosis may be associated with greater hemodynamic and right ventricular recovery in patients with intermediate-risk pulmonary embolism (PE) compared with treatment performed later.

Penumbra Launches Lightning Flash 3.0 CAVT System to Treat VTE

January 26, 2026—Penumbra announced the launch of the Lightning Flash 3.0 computer assisted vacuum thrombectomy (CAVT) system for the treatment of venous thromboembolism (VTE).

Penumbra’s CAVT Evaluated for Outcomes and Resource Utilization in Intermediate-Risk PE Patients

December 16, 2025—Penumbra announced the publication of a new study that showed that the use of the company’s computer-assisted vacuum thrombectomy (CAVT) technology for intermediate-risk pulmonary embolism (PE) may shorten length of hospital stay, reduce complications, and improve discharge outcomes without increasing mortality compared to other treatment modalities.

Primary Results From STORM-PE RCT Presented for Penumbra’s CAVT System

November 3, 2025—Penumbra, Inc. announced that results of the STORM-PE randomized controlled trial (RCT) were presented at VIVA 2025, the Vascular Interventional Advances conference.

Inquis Medical’s Aventus Thrombectomy System Studied to Treat Pulmonary Embolism

May 6, 2025—Inquis Medical recently announced that the AVENTUS trial evaluating the company’s investigational Aventus thrombectomy system met its primary endpoints, demonstrating both safety and efficacy in the treatment of acute intermediate-risk pulmonary embolism (PE).

Penumbra’s Lightning Flash CAVT Technology Evaluated in Multiple Studies

April 2, 2025—Penumbra, Inc. announced data from studies of the company’s Lightning Flash computer-assisted vacuum thrombectomy (CAVT) technology as a frontline therapy for blood clots.

E2 Raises Financing to Advance Treatment of Pulmonary Embolism

February 18, 2025—Endovascular Engineering, Inc. (E2) announced it has secured $42 million in oversubscribed Series B financing to advance its next-generation clot removal technology platform for venous thromboembolism (VTE).

Argon Commences CLEAN-PE Study of Cleaner Pro Thrombectomy System

January 9, 2025—Argon Medical Devices announced the first patient enrollment in the CLEAN-PE study, which is estimated to enroll > 100 patients at hospitals across the United States.

AngioDynamics AlphaVac F18⁸⁵ System Approved in Europe

May 21, 2024—AngioDynamics, Inc. announced European CE Mark approval of the AlphaVac F18⁸⁵ system for the nonsurgical removal of thrombi or emboli from the pulmonary arteries and for the treatment of pulmonary embolism (PE).

Endovascular Engineering Helo Thrombectomy System for Acute PE Evaluated in ENGULF Trial

May 3, 2024—Late-breaking data from the ENGULF trial showed that the dual-action Helo pulmonary embolism (PE) thrombectomy system (Endovascular Engineering [E2]) was effective and safe in treating acute PE.

The PERT Consortium Launches Pilot Program for Regional and Comprehensive PE Centers of Excellence

April 26, 2024—The PERT Consortium, a multidisciplinary, global, nonprofit organization dedicated to the care of pulmonary embolism (PE) patients, announced the launch of its Regional and Comprehensive PE Centers of Excellence pilot program.

Penumbra Lightning Flash 2.0 CAVT System Cleared by FDA and Launched

April 23, 2024—Penumbra, Inc. announced the FDA clearance and launch of Lightning Flash 2.0, the company’s next-generation computer assisted vacuum thrombectomy (CAVT) system for removal of venous thrombus and treatment of pulmonary emboli.

Thrombolex RESCUE II Study Begins Patient Enrollment

January 22, 2024—Thrombolex, Inc. announced the enrollment of the first patient in the RESCUE II study using the company’s Bashir endovascular catheter for the treatment of acute intermediate-risk pulmonary embolism (PE).

Study Uses PERT Consortium Registry Data to Examine Practice Patterns and Outcomes in High-Risk Pulmonary Embolism

January 17, 2024—In a retrospective analysis using data from the PERT Consortium registry, Kobayashi et al found high rates of in-hospital mortality and major bleeding in patients with high-risk pulmonary embolism (PE) as compared with intermediate-risk PE.

Thrombolex Bashir Catheter Cleared by FDA to Treat Acute Pulmonary Embolism

April 20, 2023—Thrombolex, Inc. announced FDA 510(k) clearance for use of the company’s Bashir and Bashir S-B endovascular catheters for the pharmacomechanical catheter-directed thrombolysis (PMCDT) treatment of acute pulmonary embolism (PE).